Gpower partners with Amorepacific to accelerate development of dual-function beauty tech devices

South-Korean-firm-Gpower-partners-with-Amorepacific-to-accelerate-development-of-dual-function-beauty-tech-devices.jpg
Gpower is actively expanding its line-up of beauty tech devices. ©Gpower

South Korean firm Gpower has signed a memorandum of understanding with Amorepacific-owned Pacific Tech to facilitate the development of beauty tech devices boasting both diagnosis and personalised skin care functions.

This collaboration, which would combine Gpower’s technologies with Amorepacific’s brand prominence, is touted as a crucial step towards providing “more differentiated beauty solutions and new value” to consumers.

The main aim is to develop beauty devices that can simultaneously perform skin diagnosis and customised skin care. The two companies will be discussing specific product development schedules and supply terms.

“As competition in the beauty device market intensifies, this partnership is expected to have a positive impact on both firms. We are very pleased to develop innovative beauty devices by collaborating with Pacific Tech, and we seek to provide new consumer experiences through the synergy between the two companies,” said Han Chang-hee, CEO of Gpower.

It is also believed that the partnership will strengthen Amorepacific’s beauty tech portfolio.

To date, Gpower has brought to market several beauty devices, such as gpskin Barrier, which claims to be able to measure transepidermal water loss (TEWL) and stratum corneum hydration (SCH) levels of the skin at the same time.

The device is built with four sensors leveraging advanced skin sensor technology that was previously only used in research labs and hospitals.

For every body part that is scanned using the tool, a detailed analysis of the skin and skin care advice based on the results are sent to the user’s gpskin mobile app via Bluetooth.

According to the firm, the system is backed by skin barrier function and moisture data of over 1 million people of all ages to deliver “scientific, objective, and personalised” recommendations.

Gpower supplies to over 40 renowned hospitals and cosmetics companies locally and around the world, including in-store applications at Kiehl’s, Dr. Ci:Labo, and Olive Young.

The gpskin Barrier has also been used in clinical studies on the prevention of neonatal atopic dermatitis and on atopy that were funded by the National Institutes of Health (NIH).

Constant innovation

In the past two years since the launch of gpskin Remedy, a home-use device that diagnoses and treats the skin, Gpower has sold more than 25,000 units of it.

Apart from AI camera analysis, by placing the sensors on the skin while connecting the device to the mobile app via Bluetooth, it examines the skin “in less than 10 seconds”.

The detailed analysis results, including areas that require more care, such as under eye and wrinkles, as well as a personalised skin care programme recommendation will then be sent to the user.

Depending on an individual’s needs, there are three main treatment modes, namely tightening, lifting, and ion boosting, which the device is calibrated to complete within seven minutes.

Each mode uses a specific technology combined with LED colours — High Frequency improves skin elasticity, fine lines, and appearance of pores; electrical muscle stimulation (EMS) helps with fine lines and smile lines; and iontophoresis enables glowing skin, accelerates skin regeneration, and maintains skin hydration.

On the mobile app, the user can select more defined skin needs, including after sun care and hydration care, and also obtain season-specific treatment recommendations.

As part of its active expansion in the beauty device market, Gpower has been adding to its at-home care line-up.

For instance, it has introduced a fully waterproof EMS pore care device called gpskin Pore New that provides real-time customised care via a selfie image analysis function.

Its collaboration with Amorepacific is expected to further speed up the rate of innovation and commercialisation in this category.